- BioSyent has received Health Canada approval for Thyconvi, the first and only levothyroxine oral solution approved in Canada for hypothyroidism management and thyroid-stimulating hormone (TSH) suppression
- Through its subsidiary, BioSyent Pharma holds the exclusive rights to register, market, sell, and distribute Thyconvi across Canada, expanding the company’s presence into endocrinology
- The liquid oral formulation is expected to offer greater flexibility in dosing and titration, particularly for patients who may face challenges with existing tablet formulations or require more consistent dose adjustments to achieve target TSH levels
- BioSyent said Thyconvi addresses an unmet need in thyroid care and plans to launch the product in Canada in the coming months, adding a new treatment option for Canadians living with hypothyroidism
Takeaways
Thyconvi gives BioSyent a differentiated way into Canadian endocrinology by offering the first liquid levothyroxine, so it can compete on convenience and dosing flexibility rather than trying to displace entrenched tablet brands on price alone.
For the market, a ready‑to‑use oral solution should be especially attractive for children, older adults, patients with swallowing difficulties, and those needing fine‑tuned TSH control, which can drive niche but steady uptake and help BioSyent build relationships with endocrinologists and primary care ahead of future launches.
Source: Globenewswire
